Anti-FcGR3A (CD16A) IgG Antibody, Biotin-Labeled

BPS Bioscience

Anti-FcGR3A (CD16A) IgG Antibody, Biotin-Labeled

7

Research Use Only

Monoclonal

Biotin

≥90%

IgG1

This anti-FcGR3A (CD16A) antibody is a purified, biotinylated, recombinant human monoclonal antibody which recognizes the human FcGR3A/CD16A protein. Fc Gamma Receptor IIIa (FcGRIIIA; FcgammaRIIIA), also known as CD16a, is a low/intermediate affinity receptor for polyvalent immune-complexed IgG. It is involved in phagocytosis, antibody-dependent cytotoxicity, and clearance of immune complexes. FcGR3A/CD16A plays a role in the activation of natural killer (NK) cells. Clinically, it serves as a marker of certain immune cells such as neutrophils. CD16 expression has been observed at the surface of T cells in patients with chronic viral infections (such as COVID-19). It is considered a potential therapeutic target to potentiate the efficacy of therapeutic antibodies used to treat solid tumors, or as direct target in hematopoietic cancers. This antibody has been tested for specific binding to purified human FcGR3A/CD16A (BPS Bioscience #79013) in an ELISA binding assay with colorimetric detection. It does not cross-react with purified human FcGR2B/CD16B.

-80°C

12352203